Aquestive Therapeutics Enters Material Definitive Agreement

TL;DR

AQST signed a big deal, filing shows. Details TBD.

AI Summary

On March 19, 2024, Aquestive Therapeutics, Inc. entered into a material definitive agreement. The company also reported other events and filed financial statements and exhibits. The exact nature of the agreement and the financial details were not specified in the provided excerpt.

Why It Matters

This filing indicates a significant new agreement for Aquestive Therapeutics, which could impact its future business operations and financial performance.

Risk Assessment

Risk Level: medium — The filing indicates a material definitive agreement, which could carry significant implications, but the lack of specific details necessitates a medium risk assessment.

Key Numbers

• 001-38599 — SEC File Number (Identifies the company's filing history with the SEC.)
• 82-3827296 — IRS Employer Identification No. (Company's tax identification number.)

Key Players & Entities

• Aquestive Therapeutics, Inc. (company) — Registrant
• March 19, 2024 (date) — Date of earliest event reported
• 30 Technology Drive Warren, NJ 07059 (location) — Registrant's Principal Executive Offices
• MonoSol Rx, Inc. (company) — Former company name

FAQ

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share AQST Nasdaq Global Market
• $4.50 — Stock"), at a public offering price of $4.50 per share. In addition, the Company has
• $69.8 m — fering are expected to be approximately $69.8 million, after deducting the underwriting

Filing Documents

• ny20024600x3_8-k.htm (8-K) — 40KB
• ny20024600x3_ex1-1.htm (EX-1.1) — 272KB
• ny20024600x3_ex5-1.htm (EX-5.1) — 17KB
• ny20024600x3_ex99-1.htm (EX-99.1) — 13KB
• ny20024600x3_ex99-2.htm (EX-99.2) — 14KB
• ny20024600x3ex5-1_image01.jpg (GRAPHIC) — 2KB
• ny20024600x3ex99-1_image01.jpg (GRAPHIC) — 2KB
• 0001140361-24-014613.txt ( ) — 576KB
• aqst-20240319.xsd (EX-101.SCH) — 4KB
• aqst-20240319_lab.xml (EX-101.LAB) — 22KB
• aqst-20240319_pre.xml (EX-101.PRE) — 16KB
• ny20024600x3_8-k_htm.xml (XML) — 4KB

01

Item 1.01 Entry into a Material Definitive Agreement. Underwriting Agreement On March 19, 2024, Aquestive Therapeutics, Inc. (the "Company") entered into an underwriting agreement (the "Underwriting Agreement") by and among the Company and Leerink Partners LLC and Piper Sandler & Co., as representatives of the several underwriters named therein (the "Underwriters"), relating to an underwritten public offering of 16,666,667 shares of the Company's common stock, par value $0.001 per share ("Common Stock"), at a public offering price of $4.50 per share. In addition, the Company has granted the underwriters a 30-day option to purchase up to an additional 2,500,000 shares of its common stock at the public offering price, less underwriting discounts and commissions. The net proceeds to the Company from the offering are expected to be approximately $69.8 million, after deducting the underwriting discount and estimated offering expenses payable by the Company. All of the shares of Common Stock in the offering are being sold by the Company. The closing of the offering is expected to occur on March 22, 2024, subject to customary closing conditions. The Company intends to use the net proceeds received from the offering, together with its existing cash and cash equivalents, primarily to advance the development and commercialization of its product pipeline, including Anaphylm (epinephrine) Sublingual Film for the treatment of severe life-threatening allergic reactions, including anaphylaxis, and Libervant (diazepam) Buccal Film for the treatment of seizure clusters in epilepsy patients aged two to five, and for working capital, capital expenditures and general corporate purposes. Based on the Company's current operating plan, it believes that the net proceeds from the offering, together with its existing cash and cash equivalents, will enable the Company to fund its planned operating expenses and capital expenditures through December 2025. The offering is being made p

01

Item 8.01 Other Events. On March 19, 2024, the Company issued a press release announcing the launch of the offering and a press release announcing the pricing of the offering. Copies of the press releases are filed as Exhibits 99.1 and 99.2, respectively, to this Form 8-K and are incorporated herein by reference.

Forward-Looking Statements

Forward-Looking Statements "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements about the Company's expectations with respect to the completion, timing and size of the offering and the expected amount and use of net proceeds from the offering. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "intends," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon the Company's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with market conditions and the satisfaction of customary closing conditions related to the offering. Additional factors that could cause actual results to differ materially from those stated or implied by our forward-looking statements are disclosed in the Company's filings with the Securities and Exchange Commission, including in the section captioned "Risk Factors" in the Company's annual report on Form 10-K for the fiscal year ended December 31, 2023. All forward-looking statements contained in this report speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. These forward-looking statements should not be relied upon as representing the Company's views a

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits (d) Exhibits. Exhibit Number Description 1.1 Underwriting Agreement, dated March 19, 2024, by and among Aquestive Therapeutics, Inc. and Leerink Partners LLC and Piper Sandler & Co., as representatives of the several underwriters named therein 5.1 Opinion of Dechert LLP 23.1 Consent of Dechert LLP (included in Exhibit 5.1) 99.1 Press Release of the Company issued on March 19, 2024 99.2 Press Release of the Company issued on March 19, 2024 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: March 21, 2024 Aquestive Therapeutics, Inc. By: /s/ A. Ernest Toth, Jr. Name: A. Ernest Toth, Jr. Title: Chief Financial Officer (Principal Financial Officer)

View Full Filing

View this 8-K filing on SEC EDGAR